Streamlining Rheumatology Olive AI Replacement with Klivira

As healthcare organizations navigate the transition following Olive AI's discontinuation, ensuring a robust and specialized solution for rheumatology prior authorizations is critical. Klivira offers a comprehensive rheumatology Olive AI replacement, designed to manage the unique complexities of this high-burden specialty.

Revenue cycle directors and prior authorization coordinators in rheumatology clinics face significant challenges, particularly with the high volume of biologic and specialty drug PAs. Replacing a system like Olive AI requires a platform that not only automates but also deeply understands the clinical and administrative nuances of rheumatology, from complex step therapy to chronic treatment re-authorizations. Klivira provides a clear path forward.

Addressing the Rheumatology Prior Authorization Burden

Rheumatology prior authorizations are among the most complex and high-volume, driven by the chronic nature of conditions like rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and lupus, and the reliance on high-cost advanced agents. The imperative for a reliable rheumatology Olive AI replacement is to maintain efficiency and minimize disruption to patient care and revenue streams.

Key Prior Authorization Triggers in Rheumatology

Biologics: adalimumab (Humira), etanercept (Enbret), infliximab (Remicade), certolizumab (Cimzia), golimumab (Simponi), ustekinumab (Stelara), guselkumab (Skyrizi), risankizumab (Skyrizi)
JAK Inhibitors: tofacitinib, baricitinib, upadacitinib (Rinvoq)
Infusion Therapy: for provider-administered biologics and other agents
Advanced Imaging: MRI for inflammatory arthritis, ultrasound-guided joint injections
DEXA Scans: for osteoporosis management in chronic steroid patients

Navigating Complex Documentation and Payer Policies

Rheumatology PAs demand meticulous documentation aligned with clinical guidelines such as the ACR Treatment Guidelines. Payers require specific criteria including ICD-10 diagnosis, disease activity scores (e.g., DAS28, CDAI, PASI, BASDAI, SLEDAI), and documentation of prior conventional DMARD trials or step therapy compliance. Klivira’s platform is engineered to manage these intricate requirements, ensuring submissions are complete and accurate.

Common Denial Reasons and How Klivira Mitigates Them

Step therapy not completed: Failure to document required prior agent trials or sequences.
Biosimilar substitution required: Denial of brand biologic when a biosimilar should be tried first.
Disease activity not documented: Missing or incomplete DAS28, CDAI, or equivalent scores.
Screening documentation gaps: Incomplete TB, hepatitis, or immunization records.
Off-indication use without supporting policy: Request for a biologic for an unsupported autoimmune condition.

Klivira's Specialized Approach for Rheumatology PA Automation

Klivira provides a robust rheumatology Olive AI replacement by integrating directly with your EMR via SMART on FHIR, automating the extraction of clinical data, and submitting PAs through various payer channels including X12 278 and payer portals. Our platform incorporates ACR-guideline-aware policy logic for step therapy sequencing, handles biosimilar substitution routing per payer mandates, and manages periodic re-authorization workflows essential for chronic rheumatology treatments.

Optimizing Rheumatology Workflows Post-Olive AI

Beyond initial PA submission, Klivira addresses specialty-specific workflow constraints such as the chronic-treatment ongoing PA burden and the variability in biosimilar substitution policies. Our system intelligently routes PAs based on medical vs. pharmacy benefit splits for the same agent, streamlining processes and reducing manual intervention. This ensures that your team can focus on patient care rather than administrative overhead, making the transition from Olive AI seamless and efficient.

Frequently asked questions

How does Klivira handle complex step therapy requirements for rheumatology biologics?

Klivira's platform incorporates ACR-guideline-aware policy logic to manage indication-specific step therapy sequencing. It automates the verification of prior conventional DMARD trials and ensures compliance with payer-specific requirements for biosimilar substitution before approving brand biologics, significantly reducing 'step therapy not completed' denials.

Can Klivira integrate with our existing EMR for rheumatology prior authorizations?

Yes, Klivira is designed for deep EMR integration, leveraging standards like SMART on FHIR. This allows for automated extraction of necessary clinical documentation, such as diagnosis codes (ICD-10), disease activity scores (DAS28, CDAI), and screening results, directly from your EMR to populate PA requests for rheumatology cases.

How does Klivira support the ongoing re-authorization process for chronic rheumatology treatments?

Our platform includes a dedicated periodic re-authorization workflow for chronic-treatment biologics. It tracks re-authorization due dates and prompts for continuous documentation of disease response, ensuring that necessary information is collected and submitted to payers in a timely manner, minimizing lapses in coverage for patients on long-term therapy.

Does Klivira manage prior authorizations for both medical and pharmacy benefit rheumatology drugs?

Absolutely. Klivira is equipped to handle the complexities of medical-vs-pharmacy benefit splits for rheumatology biologics and other agents. Our system intelligently routes PA requests based on the administration mode and specific payer policies, ensuring the correct benefit pathway is followed for each submission.

What specific payer channels does Klivira use for rheumatology prior authorizations?

Klivira connects to a wide array of payer channels, including direct integrations via X12 278 transactions, automated submissions through payer web portals, and other electronic prior authorization (ePA) methods. This comprehensive connectivity ensures broad coverage for rheumatology PAs across various payers.